Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Berkeley Lights Announces GEPAD to Attack COVID-19 and Other Viruses

Today Berkeley Lights, Inc., announced the GEPAD with the aim to accelerate the discovery of neutralizing antibodies from patient blood samples.

From Bruker Cellular Analysis 26 Mar 2020

Celltrion announces key milestones in its efforts to fight COVID-19

Celltrion Group today announced key milestones in its efforts to fight the 2019 novel coronavirus (COVID-19) pandemic.

23 Mar 2020

New understanding of signaling molecule interleukin-2 can guide drug discovery efforts

The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.

17 Mar 2020

New sepsis intervention enhances the body's bacteria-capturing neutrophil extracellular traps

Researchers at Children's Hospital of Philadelphia have developed a novel treatment for sepsis - one of the leading causes of hospital death - that enhances the body's bacteria-capturing neutrophil extracellular traps so that they more effectively capture infectious bacteria, resist degradation, and improve sepsis outcomes and survival.

5 Mar 2020

New immunotherapeutic strategy shows promise to fight off infectious biofilms

The same way baking soda breaks down grease and grime, making surfaces easier to clean, researchers at the Lewis Katz School of Medicine at Temple University now show that a new therapeutic molecule can break apart communities of harmful bacteria, opening the way for bacteria-killing antibiotics to more effectively clear out infections.

27 Feb 2020

Boosting immune cells to treat eczema

A new drug regimen is reported to have marked benefits in treating the troublesome and distressing skin condition called eczema. The study, published in February 2020 in the journal Science Translational Medicine, shows that boosting the levels of a type of immune cell called natural killer cells can be a more effective way to treat eczema in a mouse study.

27 Feb 2020

Columbia teams receive $2.1 million grant to find potential antiviral drugs for 2019-nCoV

Four research teams at Columbia University will share a $2.1 million grant to mount an aggressive effort to identify potential antiviral drugs and antibodies for use against the new coronavirus, 2019-nCoV.

20 Feb 2020

Simple, portable test can detect poisonous mushrooms in minutes

A simple, portable test that can detect the deadliest of the mushroom poisons in minutes has been developed by Agricultural Research Service scientists and their colleagues.

19 Feb 2020

New prophylactic and therapeutic avenues to fight against rabies

Rabies is still responsible for approximately 60,000 human deaths per year mostly in Asia and Africa and affects especially underserved people.

11 Feb 2020

New treatment effective at reversing the manifestations of thyroid eye disease

Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.

10 Feb 2020

New treatment target for acute kidney injury prevention revealed

Up to 10% of patients who are hospitalized or undergo surgery will experience acute kidney injury, and as many as 50% of patients in intensive care units will meet the criteria for AKI, the National Kidney Foundation has determined. Some of these patients will progress to kidney failure within months.

4 Feb 2020

Hendra antibody trial shows promise in a world-first human clinical trial

The Hendra virus is a potent pathogen transmitted to humans from animals that cause a severe and often fatal illness in both infected horses and humans. Originating from fruit bats, the virus caused an outbreak in Australia in 1994.

4 Feb 2020

New treatment target could change the outlook of patients at risk of kidney injury

Kidney injury is a dreaded complication of commonly performed procedures such as coronary angiography or cardiac surgery, often stopping physicians and patients in their tracks.

30 Jan 2020

Clinical trial to test safety, effectiveness of mAb against malaria in healthy volunteers

A Phase 1 clinical trial testing the safety and effectiveness of a monoclonal antibody (mAb) against malaria has begun enrolling healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial, sponsored by NIH's National Institute of Allergy and Infectious Diseases (NIAID), is the first to test mAb CIS43LS in humans. It aims to enroll up to 73 volunteers aged 18 through 50 years old who have never had malaria.

27 Jan 2020

GW expands clinical trial of neoadjuvant immunotherapy for high-risk cutaneous squamous cell carcinoma

The Cutaneous Oncology Program at the George Washington University (GW) Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma.

22 Jan 2020

Genetically engineered mosquitoes halt Dengue spread

A new study published in the journal PLOS Pathogens in January 2020 reports the development of mosquitoes that have been genetically modified to resist infection by several types of the dengue virus. This is the first time ever that all types of the virus have been targeted by the engineering of the mosquito DNA. Covering all virus types is essential to achieve proper disease control.

16 Jan 2020

New antibody-drug conjugate shows promising activity in salivary gland tumors

The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology.

7 Jan 2020

Bile acids help norovirus to infect cells of the small intestine

A new study led by researchers at Baylor College of Medicine and published in the Proceedings of the National Academy of Sciences reveals that human noroviruses, the leading viral cause of foodborne illness and acute diarrhea around the world, infect cells of the small intestine by piggybacking on a normal cellular process called endocytosis that cells use to acquire materials from their environment.

31 Dec 2019

New dementia vaccine may proceed to clinical trials after successful testing

A preventive treatment for dementia may proceed to clinical trials after successful animal testing.

31 Dec 2019

New antibody shows promise in active lupus

A new trial involving the use of an antibody called anifrolumab reports improvement in patients with systemic lupus erythematosus (SLE) after 52 weeks of treatment. The research, titled 'Trial of Anifrolumab in Active Systemic Lupus Erythematosus', is published in the New England Journal of Medicine.

19 Dec 2019